We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Sanofi’s COVID-19 Vaccine Generates Strong Antibody Response in Animals, Human Trials to Begin in November

By HospiMedica International staff writers
Posted on 27 Aug 2020
Sanofi’s (Paris, France) experimental COVID-19 vaccine developed jointly with Translate Bio (Lexington, MA, USA) generated high amounts of protective neutralizing antibodies in early-stage animal studies.

In its latest regulatory filing, Translate Bio has presented preclinical data on the messenger RNA vaccine which is similar to the mRNA technology adopted by Moderna Inc. More...
for its COVID-19 vaccine and prompts the body to produce a key protein from the SARS-CoV-2 virus, thus inducing an immune response. In its regulatory filing Translate Bio, which has entered into a potential USD 2 billion deal with Sanofi for the development of the COVID-19 vaccine, cited Sanofi's presentation slides showing three doses of the vaccine candidate had induced neutralizing antibodies and T-cell responses in animal studies.

Translate Bio has stated in its filing that the data “demonstrate that two immunizations of the mRNA vaccine induced high neutralizing titers that are comparable to the upper range of those observed in infected humans.” According to Translate Bio, the experimental COVID-19 vaccine developed alongside Sanofi will now be tested on humans, starting in November.

Related Links:
Sanofi
Translate Bio



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
12-Channel ECG
CM1200B
New
Radiofrequency Generator
GX1
Glucose Meter
StatStrip®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Reusable catheter patients used 35 percent fewer antibiotics compared to their single-use only counterparts. (Photo courtesy of the University of Southampton)

Reusable Intermittent Catheters Reduce Antibiotic Use Without Increasing Urinary Tract Infections

Intermittent self-catheterization, used to empty the bladder several times a day, can leave patients vulnerable to recurrent urinary tract infections and repeated antibiotic use. Reliance on single-use... Read more

Surgical Techniques

view channel
Image: Avvio Medical\'s technology combines microbubble-enhanced acoustic cavitation with smart catheter navigation to precisely target and break down ureteral stones, all without the need for routine stenting or general anesthesia (Photo courtesy of Avvio Medical)

Anesthesia-Sparing System Targets Faster Ureteral Stone Treatment

Ureteral stone care is often delayed by operating room scheduling constraints and growing wait times, leaving a gap between diagnosis and treatment. With no fundamentally new therapeutic approach introduced... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.